Graphene Manufacturing Group has named nine-time Motocross World Champion Antonio Cairoli as its brand ambassador to aid in developing its graphene-based engine oil additive, G LUBRICANT, for motorcycles and off-road vehicles. Cairoli, also a Ducati test rider, will test and provide feedback on the additive in his personal vehicles, helping refine the product for demanding off-road conditions. The additive has shown promising results in reducing fuel consumption, emissions, and friction in various tests, with further validation planned for off-road and racing uses. Additionally, independent testing by Massimo Fogliaro’s A-Team will evaluate the product under motocross competition conditions.
Graphene Manufacturing Group's new brand ambassador is motocross champion Antonio Cairoli. For readers following the Energy sector, here is Pluang's market snapshot as of Oct 19, 2026 19:15 WIB: Of 79 priced Energy-sector US stocks, 25 rose and 47 fell today. Notable prices include PSX at USD 287.14 with a -2.06% change and a typical hold time of 63 days, SM at USD 38.71 with a -2.00% change and a 2-day hold time, and PBF at USD 82.88 with a -1.94% change and a 2-day hold time.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
